| Date | Title | Description |
| 03.05.2024 | Novartis купит американскую радиофармацевтическую компанию Mariana Oncology за $1 млрд | Mariana Oncology работает над новыми методами лечения рака радиолигандами (RLT), которые еще не были протестированы на людях.
«Сделка укрепляет портфель Novartis RLT и расширяет исследовательскую инфраструктуру компании и возможности клинич... |
| 21.11.2023 | MorphoSys with positive phase 3 study results in myelofibrosis | MorphoSys AG, Planegg, Germany, announced compelling results from the Phase 3 MANIFEST-2 study evaluating pelabresib, a BET inhibitor in clinical development, in combination with the JAK inhibitor ruxolitinib versus placebo plus ruxolitinib... |
| 13.09.2023 | MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer | MorphoSys AG received the U.S. Food and Drug Administration (FDA) granted Fast Track designation for tulmimetostat, for the treatment of patients with advanced, recurrent or metastatic endometrial cancer. Tulmimetostat is MorphoSys’ third c... |
| 09.01.2023 | MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024 | MUNICH, GERMANY / ACCESSWIRE / January 9, 2023 / MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that topline data from the ongoing Phase 3 MANIFEST-2 study - a global, randomized, double-blind clinical trial exploring pelabresib, an i... |
| 14.11.2022 | Deep disappointment with MorphoSys' and Roche's Alzheimer's drug Gentenerumab | The study results announced today for the Alzheimer's drug Gantenerumab from MorphoSys's license partner Roche caused a drop in the MorphoSys share price. On Tradegate, the shares of the Planegg-based biotech company lost 18 percent compare... |
| 27.10.2022 | MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors | The findings, including encouraging preliminary efficacy data in various tumor types, were presented during the 34th EORTC-NCI-AACR Symposium
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 27, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today... |
| 29.09.2022 | Aiming for fourth nod, Sarepta files another DMD gene therapy to FDA; Axsome headed toward migraine resubmission | Sarepta Therapeutics has filed the data needed for an FDA accelerated approval, which would be the biotech’s fourth if granted by the agency.
The biotech has yet to complete confirmatory trials for those first three condi... |
| 28.07.2022 | MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022 | Conference Call Alert
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 28, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) will publish its results for the second quarter and first half year 2022 results on August 3, 2022 at 10:00 pm CEST (9:00 ... |
| 15.06.2022 | MorphoSys finds a nice, new billion-dollar home for unwanted assets in oncology pivot | MorphoSys has found a home for a couple of assets it doesn’t want anymore—a nice billion-dollar home, that is—as the German biotech shifts focus to oncology.
The company announced aftermarket Tuesday a new licensing and equity deal with HIB... |
| 22.03.2022 | MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL | MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Minjuvi is a new therapeutic opti... |
| 30.11.2021 | MorphoSys AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] | DGAP Preliminary announcement financial reports: MorphoSys AG / Preliminary announcement on the disclosure of financial statements
MorphoSys AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115... |
| 30.11.2021 | MorphoSys AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements | DGAP Preliminary announcement financial reports: MorphoSys AG / Preliminary announcement on the disclosure of financial statements
MorphoSys AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statemen... |
| 12.11.2021 | MorphoSys AG Reports First Nine Months and Third Quarter 2021 Results - Form 6-K | MorphoSys AG Reports First Nine Months and Third Quarter
2021 Results
- Monjuvi U.S. net product sales of US$ 22.0 million (€ 18.6 million), 22% growth Q-Q
- Ten abstracts, including two oral presentations, accepted at upcoming ASH
- Pelabr... |
| 11.11.2021 | MorphoSys AG Reports First Nine Months and Third Quarter 2021 Results | DGAP-News: MorphoSys AG / Key word(s): Quarterly / Interim Statement
MorphoSys AG Reports First Nine Months and Third Quarter 2021 Results
10.11.2021 / 22:01
The issuer is solely responsible for the content of this announcement.
MorphoSys A... |
| 11.11.2021 | PRESS RELEASE : MorphoSys AG Reports First Nine -2- | Research and Development (64.4) (34.2) (88%) (138.2) (86.6) (60%) Selling (32.4) (32.9) (2%) (89.0) (75.0) (19%) General and Administrative (19.4) (13.3) (46%) (60.1) (37.2) (62%) Operating Profit / (Loss) (82.4) (62.0) (33%) (183.3) 93.1 &... |
| 10.11.2021 | MorphoSys Announces Departure of Roland Wandeler | DGAP-News: MorphoSys AG / Key word(s): Miscellaneous
MorphoSys Announces Departure of Roland Wandeler
09.11.2021 / 22:01
The issuer is solely responsible for the content of this announcement.
Media Release
MorphoSys Announces Departure of R... |
| 10.11.2021 | MorphoSys Announces Departure of Roland Wandeler | Media Release
MorphoSys Announces Departure of Roland Wandeler
Planegg/Munich, Germany, November 9, 2021 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Roland Wandeler, Ph.D., has decided to step down from his position as Chief... |
| 02.11.2021 | MorphoSys AG announces Monjuvi(R) Sales for the First Nine Months and Third Quarter of 2021 and Invitation to the upcoming Conference Call on November 11, 2021 | Media Release
Planegg/Munich, Germany, November 02, 2021
MorphoSys AG announces Monjuvi® Sales for the First Nine Months
and Third Quarter of 2021 and Invitation to the upcoming
Conference Call on November 11, 2021
MorphoSys AG (FSE: MOR; N... |
| 02.11.2021 | MorphoSys AG announces Monjuvi(R) Sales for the First Nine Months and Third Quarter of 2021 and Invitation to the upcoming Conference Call on November 11, 2021 | DGAP-News: MorphoSys AG / Key word(s): 9 Month figures
MorphoSys AG announces Monjuvi(R) Sales for the First Nine Months and Third Quarter of 2021 and Invitation to the upcoming Conference Call on November 11, 2021
02.11.2021 / 12:31
The is... |
| 29.07.2021 | MorphoSys : Reports Second Quarter and First Half 2021 Results (Form 6-K) | MorphoSys AG Reports Second Quarter and First Half
2021 Results
- Monjuvi U.S. net product sales of € 14.9 million (US$ 18.0 million), 16% growth Q-Q
- MorphoSys announced and subsequently completed its acquisition of Constellation
Pharmace... |
| 28.07.2021 | MorphoSys : Reports Second Quarter and First Half 2021 Results | DGAP-News: MorphoSys AG / Key word(s): Half Year Results
MorphoSys AG Reports Second Quarter and First Half 2021 Results
28.07.2021 / 22:03
The issuer is solely responsible for the content of this announcement.
Media Release
MorphoSys AG Re... |
| 26.07.2021 | Ad-hoc: MorphoSys AG to update financial guidance for 2021 and reduce financial liabilities | Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014
Planegg/Munich, Germany, July 26, 2021
Ad hoc: MorphoSys AG to update financial guidance for 2021 and
reduce financial liabilities
Morph... |
| 15.07.2021 | MorphoSys : to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology | DGAP-News: MorphoSys AG / Key word(s): Mergers & Acquisitions
MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology
15.07.2021 / 08:00
The issuer is solely re... |
| 04.06.2021 | MorphoSys to Buy Constellation Pharmaceuticals, for $1.7 Billion | MorphoSys AG (FSE: MOR; NASDAQ: MOR), a near Munich, Germany-based commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune... |
| 03.06.2021 | CONSTELLATION PHARMACEUTICALS, INC.
Constellation Pharmaceuticals : MorphoSys to Acquire Constellation Pharmaceuticals (Form 8-K) | MorphoSys to Acquire Constellation Pharmaceuticals
Accelerates Growth Strategy by Adding Two Mid- to Late-Stage Product Candidates:
Pelabresib (CPI-0610) and CPI-0209
Bolsters Position in Hematology-Oncology and Expands into Solid Tumors
Be... |
| 02.06.2021 | MORPHOSYS AG
MorphoSys : to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma | Ad hoc release according to article 17 para. 1 MAR
Planegg/Munich, Germany and Cambridge, Mass., June 2, 2021
Ad hoc: MorphoSys to Acquire Constellation Pharmaceuticals and
Enter into Strategic Funding Partnership with Royalty Pharma
Morpho... |
| 02.06.2021 | MORPHOSYS AG
MorphoSys : to Acquire Constellation Pharmaceuticals | DGAP-News: MorphoSys AG / Key word(s): Mergers & Acquisitions
MorphoSys to Acquire Constellation Pharmaceuticals
02.06.2021 / 13:24
The issuer is solely responsible for the content of this announcement.
MorphoSys to Acquire Constellatio... |
| 02.06.2021 | MORPHOSYS AG
MorphoSys : to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma | DGAP-Ad-hoc: MorphoSys AG / Key word(s): Mergers & Acquisitions
MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma
02-Jun-2021 / 13:22 CET/CEST
Disclosure of an inside ... |
| 02.06.2021 | MORPHOSYS AG
PRESS RELEASE : MorphoSys to Acquire Constellation -2- | MorphoSys will host a conference call and webcast to discuss the transaction on June 2, 2021 at 2:00 p.m. CEST, or 8:00 a.m. EDT. The webcast and accompanying slides can be accessed in the Media and Investors section, under Conferences, of ... |
| 02.06.2021 | MORPHOSYS AG
PRESS RELEASE: MorphoSys to Acquire Constellation -2- | MorphoSys will host a conference call and webcast to discuss the transaction on June 2, 2021 at 2:00 p.m. CEST, or 8:00 a.m. EDT. The webcast and accompanying slides can be accessed in the Media and Investors section, under Conferences, of ... |
| 19.03.2021 | MORPHOSYS AG
MorphoSys : Financial Statements 2020 of MorphoSys AG (German GAAP - HGB) | Financial Statements of MorphoSys AG as of December 31, 2020
MorphoSys AG, Planegg
2
3
Management Report
SIGNIFICANT DEVELOPMENTS IN FINANCIAL YEAR 2020
The year 2020 was a very successful one for MorphoSys. Our goal is to discover, develop... |
| 19.03.2021 | MorphoSys : Financial Statements 2020 of MorphoSys AG (German GAAP - HGB) | Financial Statements of MorphoSys AG as of December 31, 2020
MorphoSys AG, Planegg
2
3
Management Report
SIGNIFICANT DEVELOPMENTS IN FINANCIAL YEAR 2020
The year 2020 was a very successful one for MorphoSys. Our goal is to discover, develop... |
| 25.01.2021 | I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer | |
| 03.08.2020 | FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population | Shares of MorphoSys were up more than 5% premarket on the Nasdaq Monday morning. Shares of Incyte were also up more than 5% premarket, on the same exchange.
Monjuvi is a monoclonal antibody that targets CD19, the same antigen target used by... |
| 14.01.2020 | Incyte pays MorphoSys $750M upfront in lymphoma drug partnership | Under the deal, both companies will develop and commercialize tafasitamab in the U.S., while Incyte will have exclusive commercialization rights outside the U.S. Incyte is paying MorphoSys $750 million upfront and making a $150 million equi... |
| 30.12.2019 | MorphoSys files for approval of drug for hard-to-treat lymphoma patients | “The BLA submission marks a significant milestone in MorphoSys’ history and demonstrates our dedication to address the high medical need in relapsed or refractory DLBCL,” MorphoSys chief development officer Malte Peters said in a statement.... |
| 25.06.2019 | SQZ, Erytech kick off $57M cell therapy partnership; Jean-Paul Kress lands new CEO gig at MorphoSys | → In a marriage of two technologies meant to make cell therapies more powerful, SQZ Biotech is teaming up with France’s Erytech Pharma for a collaboration, with $57 million reserved for the first project and $50 million for... |
| 19.02.2019 | AbbVie scores speedy review for RA drug upadacitinib; Merck KGaA wins CRISPR patent | → AbbVie $ABBV has high hopes, projecting peak potential sales of $6.5 billion, for its oral JAK1 inhibitor upadacitinib for rheumatoid arthritis, which is up against well-entrenched rivals. On Tuesday, the drugmaker said ... |
| 08.02.2019 | MorphoSys taps Bavencio lead for US operations; Two top FDA officials move to industry | → Having built out a commercial footprint in the US and led the launch of Bavencio for Merck KGaA, David Trexler is taking up a new role as president of German biotech Morphosys’ US subsidiary. Following a dual listing on the... |
| 05.02.2019 | Sanofi reports positive data for myeloma drug isatuximab, but competitive uphill battle lies ahead | The study enrolled 307 patients in 24 countries, who were randomized to receive Celgene’s Pomalyst (pomalidomide) and the steroid dexamethasone – a common “backbone” treatment for the disease – with or without isatuximab. Bristol-Myers Squi... |
| 09.04.2018 | Term Sheet — Monday, April 9 | BIG PLAYS
Good morning, Term Sheet readers.
Paid Content What you need to know about growing cyberattacks From ExtraHop
BOMBSHELL DEAL: This morning, Novartis CEO Vasant Narasimhan announced the company would buy gene-therapy developer AveX... |
| 23.03.2018 | MorphoSys seeks $150M IPO to fund late-phase anticancer push | MorphoSys has filed to raise $150 million in a Nasdaq IPO. The listing will enable MorphoSys to pump $225 million into the development of MOR208 to establish the anti-CD19 antibody as a rival to CAR-T therapies and other therapeutics in a p... |
| 07.03.2017 | Roche is bringing back gantenerumab from the dead, taking another stab at Alzheimer’s PhIII | Marlies Sproll, MorphoSys
Alzheimer’s drugs are expensive to test and unlikely to succeed, but they are also hard to kill.
More than two years after gantenerumab failed decisively in treating early-stage Alzheimer’s, Roche ... |
| 17.11.2016 | J&J takes one of its top blockbuster prospects to the FDA, in search of a big approval | MorphoSys CSO Marlies Sproll
Hot on the heels of a new round of Phase III data showing that their IL-23 drug guselkumab handily beat out Humira in treating severe plaque psoriasis, J&J has submitted the drug for approv... |
| 10.08.2015 | MorphoSys and G7 Therapeutics sign alliance | |
| - | FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population | The Food and Drug Administration has approved a new drug for patients with an aggressive form of lymphoma who have failed on prior treatment, but are not eligible for stem cell transplants.
MorphoSys, based near Munich, Germany, and Wilming... |
| - | Incyte pays MorphoSys $750M upfront in lymphoma drug partnership | A German biotech company developing a drug for blood cancers has signed a development and commercialization deal with a U.S. based firm worth up to $2 billion.
MorphoSys, headquartered near Munich, said Monday that it had inked the deal wit... |
| - | MorphoSys files for approval of drug for hard-to-treat lymphoma patients | A German biotech company hopes to win approval for a drug developed especially for certain lymphoma patients ineligible for currently available treatments.
Munich-based MorphoSys said Monday that it had filed an approval application with th... |
| - | Sanofi reports positive data for myeloma drug isatuximab, but competitive uphill battle lies ahead | A drug under development for the blood cancer multiple myeloma has posted positive Phase III data, its developer said Tuesday.
Paris-based drugmaker Sanofi said the registration-directed Phase III ICARIA-MM study of the drug, isatuximab, ha... |
